Impact of Lynch syndrome, BRAF<sup>V600E</sup>, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts.
Distribution of the number of citations over years.